Commercial update on vitiligo
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Clinuvel Pharmaceuticals Limited has released a commercial update on the vitiligo market, focusing on the efficacy of SCENESSE® and current treatment standards. The update discusses the effectiveness of narrowband UVB therapy and various JAK inhibitors in treating extensive vitiligo, highlighting the need for effective therapies. The announcement aims to provide benchmarks for stakeholders regarding the clinical trials of afamelanotide and adjunct NB-UVB therapy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Update - SCENESSE in vitiligo
- CLINUVEL implements strategic reorganisation to refocus on U.S. markets
- CLINUVEL strategic reorganisation to refocus on U.S. markets
- SCENESSE® approved for EPP in Canada
- CLINUVEL publicly files 20-F to U.S. SEC
Later from Clinuvel Pharmaceuticals
- A decade of profitability provides U.S. expansion foundation
- Appendix 4E and Annual Report to Shareholders 2026
- CLINUVEL considers Nasdaq listing, ASX delisting
- A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
- CLINUVEL files NEURACTHEL Instant dossier
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals